Phoenix WNL to handle 2x2 crossover study with multip group [Software]

posted by ElMaestro  – Denmark, 2014-06-29 01:23 (3950 d 06:49 ago) – Posting: # 13166
Views: 27,318

Hello Zan,

I don't speak WNL but:

❝ 1. is it acceptable to just assign 4 periods to the 4 dosing days? If so,

❝ In the model specification: Treatment+Sequence+Period

❝ and in the variance structure--Random effect: Subject(Sequence).


That would be a little untraditional with four period levels. But it can be done and it is a little like working with period in group. What's the title of your study? (If it is something like "A two-treatment, two-period, two-sequence bioequivalence study blah blah" then you almost have the answer right there).

❝ 2. Can we still keep these 2 periods and add a Group term to these subjects (eg. Group 1 and Group 2)?. If so, in the model specification:

❝ Treatment+Sequence+Period+Group


Yes, much better, this is what I would do.

❝ but in the variance structure, I dont know what is appropriate to be added in the Random effect field. Should it be Subject(Sequence*Group).


Oh here we go again: Depending on your data listing you can probably just write Subject.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
23 visitors (0 registered, 23 guests [including 6 identified bots]).
Forum time: 08:13 CEST (Europe/Vienna)

The true Enlightenment thinker, the true rationalist,
never wants to talk anyone into anything.
No, he does not even want to convince;
all the time he is aware that he may be wrong.    Karl R. Popper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5